KFK. A. Firsov

K. A. Firsov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


K. A. Firsov has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rare Tumors of the Prostate: a Review of the Literature and Case Series

    by G. I. Akhverdieva, A. B. Lukianchenko, M. G. Lapteva, K. A. Firsov, Г. И. Ахвердиева, А. Б. Лукьянченко, М. Г. Лаптева, К. А. Фирсов

    The article presents a literature review dealing with rare mesenchymal tumors of the prostate, illustrated by a series of corresponding clinical cases. Information on the prevalence of these neoplasms, their clinical manifestations, and CT and MRI features are briefly summarized. Five rare cases of mesenchymal tumors of the prostate in patients of various ages (from 6 months to 74 years) who underwent different examinations including pelvic CT/MRI with intravenous contrast enhancement and treatment at the N.N. Blokhin National Medical Research Center of Oncology are described. The imaging appearance of the identified tumors in all 5 patients as large, heterogeneous, solid masses with fairly distinct, smooth or wavy contours had no characteristic features (before and after intravenous contrast enhancement), which did not allow us to specify the nature of the tumor process. Conclusion : accurate recognition of rare mesenchymal neoplasms of the prostate using various radiological methods is extremely difficult and practically impossible; therefore, the final diagnosis of such lesions should be based on histological and immunohistochemical data.

  • Open Access

    Therapy-induced neuroendocrine prostate cancer

    by M. P. Korchagin, K. A. Firsov, A. S. Krylov, V. B. Matveev

    Treatment-induced neuroendocrine prostate cancer (t-NEPC) is a rare and aggressive form of the disease, driven by the tumor's adaptive response to standard androgen deprivation therapy (ADT). Although its primary detection rate is low, t-NEPC accounts for up to 30% of cases of progressive prostate cancer (PCa), according to large-scale international studies. However, despite a significant increase in publications in recent years, many aspects of t-NEPC diagnosis and treatment remain controversial and require validation through large-scale research. This article presents a clinical case of t-NEPC and reviews current data on the molecular-genetic mechanisms and key signaling pathways underlying neuroendocrine differentiation. The aim of this publication is to expand the evidence base and improve the understanding of the clinical manifestations, diagnostic challenges, and therapeutic strategies for this rare disease.

  • Open Access

    Ewing sarcoma: Clinical case and literature review

    by A. K. Zarenkova, F. I. Salimzyanov, M. E. Abramov, M. S. Gileva, K. A. Firsov, A. A. Rumyantsev

    This article presents a clinical case of treatment of a female patient with Ewing Sarcoma of the kidney. Currently, treatment standards haven’t yet been developed due to the rarity of this pathology. We describe our own experience of drug treatment of Ewing sarcoma of the kidney recurrence after surgery.

  • Open Access

    Aspects of hypogonadism in oncological patients receiving antitumor treatment. Literature review

    by M. E. Abramov, E. R. Israelyan, A. S. Tsareva, A. A. Rumyantsev, K. A. Firsov, V. B. Matveev

    Recent development of anticancer drug therapy and the improvement of surgical interventions have led to better oncological treatment outcomes for most patients. The introduction of targeted therapy and immuno-oncological agents into clinical practice has allowed previously incurable diseases to be transformed into chronic conditions. While focusing solely on the effectiveness of therapy, many practicing oncologists often pay little attention to another aspect – toxicity. Hypogonadism is a relatively common adverse event (AE) in men undergoing anticancer treatment. The symptoms of this AE (asthenia, erectile dysfunction, mood variability) are often mistaken for complications of drug therapy. Both chemotherapy (CT) and targeted therapy, as well as immunotherapy, can lead to hypogonadism. According to various authors, platinum-based agents can cause the development of hypogonadism in 50 % of cases among young men. Oxaliplatin-containing regimens may result in a decrease in sperm concentration following adjuvant CT for colorectal cancer. Germ cell tumors of the testis, which have high sensitivity to cisplatin-based CT, are among the most treatable malignant neoplasms, even with metastatic processes. The first stage of treatment for germ cell tumors is orchiectomy, which in itself contributes to the development of hypogonadism. Furthermore, when undergoing CT, the risk of this AE increases significantly, up to 50 % in some publications. Considering that this condition affects men of reproductive age with a very high life expectancy, careful monitoring of total testosterone levels is necessary. Uncorrected hypogonadism can lead to various late AEs: obesity, metabolic syndrome, cardiovascular pathology, and osteopenia.This literature review examines various aspects of hypogonadism in men receiving anticancer treatment and its impact on the development of late complications.

  • Open Access

    Solitary fibrous tumor of the prostate: clinical case and literature review

    by K. A. Firsov, F. I. Salimzyanov, O. A. Khalmurzaev, A. I. Koltunova, O. T. Khvan, V. B. Matveev

    Solitary fibrous tumor of the prostate is an extremely rare neoplasm of mesenchymal nature. To date, about 40 cases of this pathology have been described in international literature. Solitary fibrous tumors are asymptomatic for a long time and are usually an incidental radiological examination. To differentiate a solitary fibrous tumor from other mesenchymal neoplasms, it is necessary to conduct an immunohistochemical study to determine STAT6 expression. The main and most effective method of treatment is surgery. In this article we present a unique clinical case of a patient with synchronous tumors: malignant solitary fibrous tumor of the prostate (risk of metastasis (WHO 2020) intermediate); prostate cancer stage II (pT2N0M0R0, Gleason 6 (3 + 3)).